RJFSA
MYGN icon

Raymond James Financial Services Advisors’s Myriad Genetics MYGN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,846
Closed -$294K – 2892
2019
Q1 		$294K Buy
+8,846
New +$269K ﹤0.01% 2255
2018
Q4 		– Sell
-4,458
Closed -$205K – 2729
2018
Q3 		$205K Buy
+4,458
New +$198K ﹤0.01% 2522

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Raymond James Financial Services Advisors's MYGN Position: Q2 2019 in Review

Raymond James Financial Services Advisors sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 8,846 shares — an estimated $294K sold.

Raymond James Financial Services Advisors first reported a position in MYGN in Q3 2018 and held it in 2 quarters. The position peaked at $294K in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • Raymond James Financial Services Advisors reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 8,846 Myriad Genetics shares in Q2 2019, an estimated $294K.
  • Raymond James Financial Services Advisors first reported a position in Myriad Genetics in Q3 2018 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Myriad Genetics position peaked at $294K in Q1 2019.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2019, filed 6 Aug 2019.